

\*\*\*\*Published July 2015\*\*\*\*

## MarketVIEW: Epstein-barr virus vaccines (CAT: VAMV056)

<b>Product Name</b>	:	<b>MarketVIEW: Epstein-barr virus vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (.pdf) + 1 forecast model (.xls)
<b>Therapeutic Area</b>	:	Novel vaccines
<b>Publication date</b>	:	July 2015
<b>Catalogue No</b>	:	VAMV056

### Background

**Epstein-barr virus (EBV)** is a herpesvirus family that exclusively infects humans, over 95% of adults worldwide are infected. Primary EBV infections that occur in adolescence or early adulthood often result in infectious mononucleosis (IM), characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever; complications can occur in around 1% of patients. Infectious mononucleosis is associated with an increased risk of Hodgkin lymphoma. EBV is also associated with a variety of malignancies, including gastric carcinoma, nasopharyngeal carcinoma, Hodgkin lymphoma and Burkitt lymphoma. EBV caused ~1% of all global cancers in 2002. EBV also causes Post transplant lymphoproliferative disorder (PTLD), a complication of solid organ transplants (SOT) and allogeneic hematologic stem cell transplants (HSCT).

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Epstein-barr virus (EBV) vaccines across Western economies until 2035. The model contains value (\$ m) and volume (mio doses) predictions per vaccine target segment along with timeframe, pricing and penetration estimates for three target product profiles (TPPs). The product also includes an in depth review of latest EBV epidemiological trends, treatments/guidelines and latest developments in R&D.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Ebola virus, current and past outbreaks. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

### PRODUCT CONTENTS:

**Published July 2015 (CAT No: VAMV056)**

\*\*\*\*This product is composed of one forecast model (.xls) and a summary presentation (.pdf)

Contents  
Author's note  
Executive Summary  
Commercial model: key model outputs  
EBV vaccines: global sales, by target population, 2015-2035 (\$m)  
EBV vaccines: global sales, seronegative adolescents, 2015-2035 (\$m)  
EBV vaccines: global sales, college students, 2015-2035 (\$m)  
EBV vaccines: global sales, transplant recipients, 2015-2035 (\$m)  
EBV vaccines: global sales, cancers, 2015-2035 (\$m)  
EBV vaccines: global volume per segment, 2015-2035 (doses)  
EBV vaccines: modeling commercial potential  
Markets for EBV vaccines  
The role of an EBV vaccine  
EBV vaccines: potential access points  
EBV prophylactic vaccine: target product profile  
EBV cancer therapeutic vaccine: target product profile  
EBV transplant therapeutic vaccine: target product profile  
EBV vaccines: unresolved questions  
Key model parameters  
Dosing, pricing, penetration and compliance rates  
Vaccine R&D pipeline  
Vaccine R&D pipeline: clinical studies  
EBV: disease background and epidemiology  
EBV: the pathogen  
EBV antibody prevalence, by race/ethnicity and age, 2003-10, US  
Epstein-barr virus: immune response  
Epstein-barr virus: associated with malignancies  
Global number of infection-attributable cancer cases, 2002  
Epstein-barr virus associated cancers: statistics  
Global deaths due to EBV-attributable malignancies, by cancer type, region and age, 2010  
Epstein-barr virus: EBV malignancies by region

**Continued.....**

Epstein-barr virus malignancies: deaths by age  
Post transplant lymphoproliferative disorder (PTLD)  
Epstein-barr virus: PTLD incidence in kidney transplants  
Infectious mononucleosis  
Epstein-barr virus: IM associations  
Methodology/backup slides  
Bibliography  
About **VacZine Analytics**  
Disclaimer

**PAGES: ~54 slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand model TX vaccine (MS Excel-based)**

Title sheet  
Charts – value  
Charts – by country (2025)  
Value summary  
Charts – volume  
Volume summary  
Adolescents =>  
US (11 years)  
Germany  
France  
UK  
Italy  
Spain  
Other Europe  
College students =>  
US  
Germany  
France  
UK  
Italy  
Spain  
Other Europe  
Transplants =>  
US  
Germany  
France  
UK  
Italy  
Spain  
Other Europe  
Cancers =>  
US  
Germany  
France  
UK



**Continued.....**

Italy  
Spain  
Other Europe  
Sources  
Total population  
11-year-olds  
Cancer incidence  
Number of US transplants  
Forecast HSCTs  
Forecast kidney transplants  
Country income groups  
PTLD - incidence paediatrics  
Global cancers  
Global EBV deaths  
Back page

**Worksheets ~ 55 interconnected**

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5800.00**# (Region license)\*
- PRESENTATION OR MODEL ONLY - USD **\$4995** (Region license)\*

# Indicative rate only. Prevailing rate applied to date of transaction.

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

1. Cohen JI. Epstein-barr virus vaccines. *Clin Transl Immunology*. 2015 Jan 23;4(1):e32.
2. Balfour HH Jr. Progress, prospects, and problems in Epstein-Barr virus vaccine development. *Curr Opin Virol*. 2014 Jun;6:1-5.
3. Khan G and Hashim MJ Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. *Infect Agent Cancer*. 2014 Nov 17;9(1):38.
4. Dempsey AF et al. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus. *Vaccine*. 2012 Apr 21.
5. Jönsson B et al. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. *Hum Vaccin Immunother*. 2012 Sep;8(9):1360-3.
6. Cohen JI et al. The need and challenges for development of an Epstein-Barr virus vaccine. *Vaccine*. 2013 Apr 18;31 Suppl 2:B194-6.
7. Cohen JI et al. Epstein-Barr virus: an important vaccine target for cancer prevention. *Sci Transl Med*. 2011 Nov 2;3(107):107fs7
8. Sokal EM. et al Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. *J Infect Dis*. 2007 Dec 15;196(12):1749-53.
9. Hui EP et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. *Cancer Res* 2013, 73:1676-1688
10. Taylor GS et al. A Phase I Trial in UK Patients with EBV-Positive Cancer. *Clin Cancer Res* 2014; 20: 5009–5022
11. IARC. Epstein-barr Virus. Available at: [monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-6.pdf](http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-6.pdf)
12. Balfour HH Jr et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. *J Infect Dis*. 2013 Oct 15;208(8):1286-93.
13. Balfour HH Jr et al. Infectious mononucleosis. *Clin Transl Immunology*. 2015 Feb 27;4(2):e33.
14. Parkin DM et al. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer*. 2006 Jun 15;118(12):3030-44.
15. Razak AR et al. Nasopharyngeal carcinoma: the next challenges. *Eur J Cancer* 2010;46:1967–78.
16. Khan G and Hashim MJ Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. *Infect Agent Cancer*. 2014 Nov 17;9(1):38.
17. Marques HH et al. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients. *Rev Soc Bras Med Trop*. 2014 Sep-Oct;47(5):543-6.
18. García-Cadenas I et al. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. *Bone Marrow Transplant*. 2015 Apr;50(4):579-84.
19. OPTN / SRTN 2012 Annual Data Report U.S. Department of Health and Human Services. Health Resources and Services Administration. June 2014.
20. Morton M et al. Post-Transplant Lymphoproliferative Disorder in Adult Renal Transplant Recipients: Survival and Prognosis. *Leuk Lymphoma*. 2015 May 15:1-23.
21. Balfour HH Jr et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. *J Infect Dis*. 2013 Jan 1;207(1):80-8.
22. Crawford DH et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. *Clin Infect Dis*. 2006 Aug 1;43(3):276-82.
23. Chen CY et al. A large-scale seroprevalence of Epstein-Barr virus in Taiwan. *PLoS One*. 2015 Jan 23;10(1):e0115836.
24. Xiong G et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. *PLoS One*. 2014 Jun 10;9(6):e99857.
25. Rosdahl N. et al Infectious mononucleosis in Denmark. Epidemiological observations based on positive Paul-Bunnell reactions from 1940–1969. *Scand. J. Infect Dis*. 1973;5(3):163–170.
26. Hjalgrim H et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. *N Engl J Med*. 2003 Oct 2;349(14):1324-32.
27. Handel AE et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PLoS One*. 2010 Sep 1;5(9). pii: e12496.
28. Pakpoor J et al. Epstein-Barr virus and multiple sclerosis: association or causation? *Expert Rev Neurother*. 2013 Mar;13(3):287-97.
29. Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States *MMWR*. July 25, 2014 / 63(29):620-4
30. Higher Education—Institutions and Enrollment 1980 to 2009. Available at: <http://www.census.gov/compendia/statab/2012/tables/12s0278.pdf>.

31. Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: <http://www.cibmtr.org>
32. Passweg JR et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014 Jun;49(6):744-50.
33. Pariente M [Age distribution of serological profiles of Epstein-Barr virus infection: review of results from a diagnostic laboratory]. Enferm Infecc Microbiol Clin. 2007. Feb;25(2):108-10
34. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available at: [http://globocan.iarc.fr/Pages/summary\\_table\\_site\\_prev\\_sel.aspx](http://globocan.iarc.fr/Pages/summary_table_site_prev_sel.aspx)
35. Macsween KF. Epstein-Barr virus – recent advances. The Lancet Infectious Diseases. Vol 3. March 2003

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and "the spiral logo" are UK Registered Trademarks, 2009